Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth-Ayerst To Produce Enbrel At Former Glaxo Wellferon Site

Executive Summary

Wyeth-Ayerst plans to manufacture the rheumatoid arthritis therapy Enbrel at a West Greenwich, R.I. biopharmaceutical facility purchased from Glaxo.

You may also be interested in...



Immunex Enbrel Sales Capped At $800 Mil. With Current Production Capacity

Sales of Immunex' rheumatoid arthritis drug Enbrel (etanercept) in the U.S. are capped at $800 mil. a year at the current manufacturing capacity, Immunex said in an Aug. 9 Securities & Exchange Commission filing.

Immunex Enbrel Sales Capped At $800 Mil. With Current Production Capacity

Sales of Immunex' rheumatoid arthritis drug Enbrel (etanercept) in the U.S. are capped at $800 mil. a year at the current manufacturing capacity, Immunex said in an Aug. 9 Securities & Exchange Commission filing.

Glaxo Manufacturing Initiative Will Yield $600 Mil. Annual Savings

Glaxo Wellcome estimates that its manufacturing streamlining initiative "will be earnings enhancing in 2000" and will generate an annual benefit of over $600 mil. (L370 mil.) per annum in 2003.

Related Content

UsernamePublicRestriction

Register

PS034768

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel